Immunocore (NASDAQ:IMCR) Now Covered by Analysts at UBS Group

UBS Group began coverage on shares of Immunocore (NASDAQ:IMCR) in a research note released on Thursday morning, MarketBeat.com reports. The brokerage issued a sell rating and a $24.00 price target on the stock.

A number of other equities analysts have also commented on IMCR. Oppenheimer reiterated an “outperform” rating and issued a $89.00 price objective (up from $87.00) on shares of Immunocore in a research note on Friday, August 9th. Needham & Company LLC dropped their price objective on Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a research note on Tuesday, September 17th. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Tuesday, September 17th. Guggenheim lowered shares of Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. Finally, Barclays decreased their price objective on shares of Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Immunocore presently has a consensus rating of “Moderate Buy” and an average target price of $75.17.

Immunocore Stock Up 2.2 %

IMCR opened at $33.20 on Thursday. Immunocore has a twelve month low of $29.72 and a twelve month high of $76.98. The company has a debt-to-equity ratio of 1.31, a quick ratio of 5.15 and a current ratio of 5.17. The business has a 50 day moving average price of $33.40 and a 200 day moving average price of $41.34. The firm has a market cap of $1.66 billion, a P/E ratio of -26.64 and a beta of 0.72.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.25. The business had revenue of $75.40 million during the quarter, compared to the consensus estimate of $74.58 million. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. Immunocore’s quarterly revenue was up 26.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.37) EPS. Research analysts forecast that Immunocore will post -1.67 EPS for the current year.

Hedge Funds Weigh In On Immunocore

Several institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its holdings in Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after buying an additional 3,053 shares during the period. Exchange Traded Concepts LLC increased its holdings in Immunocore by 40.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after purchasing an additional 1,461 shares in the last quarter. Connective Portfolio Management LLC acquired a new stake in shares of Immunocore in the 3rd quarter valued at about $218,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Immunocore in the second quarter valued at about $3,686,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Immunocore by 37.2% during the second quarter. The Manufacturers Life Insurance Company now owns 121,753 shares of the company’s stock worth $4,126,000 after buying an additional 33,003 shares during the period. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.